DFO chelation was enhanced by physiological concentrations of albumin from iron citrate, and co addition of DFP further accelerated this effect. Lcd low transferrin bound iron, is a heterogeneous number of iron species, generally found in iron overload conditions at 1 10uM when transferrin saturation strategies 100% 1. NTBI is vital since it is thought to be the primary Checkpoint inhibitor mechanism through which the myocardium and endocrine cells become overloaded with iron in conditions associated with excessive human body iron 2. Mainstream chelation treatment with deferoxamine infusion achieves steady-state DFO levels no higher than 10uM, clearing only a portion of NTBI during the infusion 3, with NTBI quickly returning to pre chelation levels within minutes of the infusion ending 3, 4. Partial NTBI removal throughout infusion is not simply linked to the plasma concentration of DFO reached as in vitro studies show that merely a sub fraction of plasma NTBI can be directly chelated by DFO also at higher DFO levels 5. This might reflect the relative unavailability of oligomeric and polymeric Plastid species of iron citrate 6, 7 or albumin bound species 6, 8 to direct chelation by DFO. Imperfect NTBI treatment can be seen with other chelation monotherapies. As an example, deferiprone monotherapy shows only partial NTBI removal 9, 10 together with transient and incomplete removal of a redox active subfraction of NTBI called labile iron 11, 12 to plasma. Patients treated with deferasirox monotherapy also show partial removal of NTBI 13, even though LPI is gradually removed partly due the long plasma residency of this drug 12. There is for that reason considerable curiosity about creating chelation sessions that eliminate NTBI more effectively, in order to minimize uptake into target areas. In principle, by combining DFO with DFP, enhanced removal of NTBI might be achieved. While successive use angiogenesis in vitro of DFO and DFP has been shown to reduce the duration of contact with LPI 11, the shuttling of NTBI onto DFO by DFP hasn’t been specifically confirmed, nor have the circumstances under which all NTBI species may be removed from plasma been elucidated. Mixed ligand therapy is a nice-looking method nevertheless, when a small kinetically labile ligand, such as DFP, is combined with a more substantial hexadentate chelator with a greater stability for iron binding, such as DFO because a marked synergism of metal chelation may appear. The effective mix of two ligands to enhance chelation costs is demonstrated for a range of materials 14. Typical examples are nitrilotriacetate iron shuttling from salicylic acid/EDTA for plutonium removal 17, penicillamine/diethylene triamine pentaacetic acid for copper removal 16 and transferrin to DFO 15. MLT for iron overload applying DFP with DFO, frequently known as combination therapy has been used clinically and benefits to iron balance 18 and myocardial iron deposition 19 have been shown.